

Press Release

VISTA VACCINE PROVIDES PREMIER PROTECTION FOR CATTLE

---Vista[®] 5 SQ vaccine study conducted, proved efficacious in the prevention of BRD---

Summit, NJ (April 7, 2011) – Intervet/Schering-Plough Animal Health recently conducted a research comparison of Vista[®] 5 SQ, a new product in the Vista[®] vaccine line. The Vista vaccine line provides dairy producers with the most complete protection available against respiratory and reproductive diseases. Vista 5 SQ is a modified live viral (MLV) vaccine administered to cattle as a prevention of bovine respiratory disease (BRD), more commonly known as pneumonia. Long-term effects of pneumonia include a negative impact on growth, reproductive performance, milk production and longevity.

The Vista vaccine line protects against Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea (BVD Type 1 and Type 2), Parainfluenza3 (PI3), Bovine Respiratory Syncytial Virus (BRSV), leptospirosis, vibriosis, Mannheimia haemolytica and Pasteurella multocida. The Vista 5 SQ vaccine is recommended for the vaccination of healthy non-pregnant cattle, 3 months of age or older.

“Dairy producers can trust Intervet/Schering-Plough Animal Health to always provide high-quality, cost effective animal-health products,” says Scott Nordstrom, D.V.M., the director of dairy technical services for Intervet/Schering-Plough Animal Health. “Vista 5 SQ is proven to fight the most common respiratory diseases, while maximizing performance and minimizing stress in dairy cattle.”

Proven Protection

Efficacy of the 5 SQ component was demonstrated in a study involving 612 calves. The comparison study consisted of a 60-day preconditioning phase and a finishing phase. The preconditioning phase included two treatment groups of cattle, which were randomly separated and assigned a group. One group was treated with a single, needle-free vaccination, while the second group received a single vaccination followed by a revaccination at day 11. In the finishing phase one group was treated with Vista 5 SQ and the other group was given no respiratory MLV.

The one-dose vs. two-dose comparison research data revealed that during the preconditioning phase there was no significant difference in antibody production. However, the study did prove that the single vaccinated cattle possessed a lower BRD morbidity rate when compared to revaccinated cattle group.

“For producers the Vista 5 SQ can reduce the total number of head infected by BRD. With less cattle infected, producers have a higher percentage of growth, reproductive performance, milk production and longevity in their cattle,” says Nordstrom. “The usage of Vista 5 SQ will positively impact a production because more cows will stay on feed and there will be a reduction of respiratory causalities.”

The research also concluded that there was little to no difference between the average daily gain, dry-matter intake and weight of the respective experiment groups. However, the revaccination treatment group had a more efficient feed to gain ratio.

Study Conclusion

Ultimately, the study established that Vista 5 SQ given in one-dose was as effective as a two-dose practice. Even though there were differences in feed efficiency and morbidity, the overall efficacious was the same for each treatment group. However, a producer still needs to consult their veterinarian before deciding to switch to a single vaccination program.

“If properly implemented, this modified-live vaccine (MLV) can decrease morbidity and associated negative economic impacts from BRD,” Nordstrom says. “When all's said and done, our goal is to provide high-quality products and secure serenity for our producers. That is why we produce Vista, to provide producers with animal-health stability.”

About Intervet/Schering-Plough Animal Health

Intervet/Schering-Plough Animal Health, based in Boxmeer, the Netherlands, is focused on the research, development, manufacturing and marketing of animal health products. The company offers customers one of the broadest, most innovative animal health portfolios, spanning products to support performance and to prevent, treat and control disease in all major farm and companion animal species. Intervet/Schering-Plough Animal Health; subsidiaries of Merck & Co. Inc., Whitehouse Station NJ, USA. For more information, visit www.intervet.com.

About Merck

Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching programs that donate and deliver our products to the people who need them. For more information, visit www.merck.com.

###

